Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China

Each study participant will receive an injection of PENTAXIM® at 2, 3, and 4 months of age and will be monitored for safety through the entire study period.

The duration of each participant in the trial will be approximately 3 to 4 months.

• DTacP IPV//PRP~T combined vaccine: PENTAXIM® (Biological), also known as PENTAXIM®: 0.5 mL, Intramuscular

Primary outcomes

• Description of the Safety profile in terms of solicited injection site and systemic reaction, and serious adverse events after each vaccination with PENTAXIM® vaccine [Day 0 for up to 3 months post vaccination]: Solicited injection site: Tenderness, Redness, and Swelling. Solicited Systemic reaction: Fever (Temperature), Vomiting, Abnormal crying, Drowsiness, Loss of Appetite, and Irritability

Sex: All, ages: 60 Days to 74 Days, accepts healthy volunteers

Inclusion Criteria:

* Aged 2 months (60 to 74 days) inclusive on the day of the first study visit
* Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative
* Subject and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures.

Exclusion Criteria:

* Participation or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy since birth, or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks since birth)
* Known systemic hypersensitivity to any of the vaccine components, or history of a life threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances
* Clinically significant illness, according to investigator judgment, at a stage that could interfere with trial conduct or completion
* Evolving encephalopathy
* Receipt of immune globulins, blood or blood-derived products since birth
* Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis diseases or Haemophilus influenzae type b infection
* Receipt of any other vaccine in the 14 days preceding the first trial vaccination or planned receipt of any vaccine in the 14 days following the first trial vaccination
* Acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (axillary temperature ≥37.1°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
* Contraindications to vaccination according to PENTAXIM® summary of product characteristics (SPC) or leaflet
* In an emergency setting, or hospitalized involuntarily
* Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.

• Medical Director, Study director, Sanofi Pasteur SA